In a research report released Thursday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on shares of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), with …
Cowen’s healthcare analyst Phil Nadeau weighed in today with a few insights on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), following Monday’s news that the company’s exploratory Phase 2a …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) received another set of praises from analysts at Piper Jaffray in a research report released today. The research team, …
GW Pharmaceuticals plc (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced positive …
The legalities of hemp have come into question over the last few years based on its close relationship to marijuana, even though they …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial …
GW Pharmaceuticals PLC-ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that the …
Wall Street is in the heart of earnings season with three key biotechnology stocks slated to announce their quarterly financial results this week. …
Piper Jaffray analyst Joshua Schimmer was out pounding the table on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), reiterating an Overweight rating with a price target of $147, which …
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that …
